PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-21.98%
Negative net income growth while RVPH stands at 34.18%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
22.78%
D&A growth of 22.78% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
128.24%
SBC growth well above RVPH's 1.78%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-92.68%
Both reduce yoy usage, with RVPH at -135.68%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
314.60%
A yoy AP increase while RVPH is negative at -120.32%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
26.98%
Some yoy usage while RVPH is negative at -201.92%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-101.99%
Negative yoy while RVPH is 100.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-120.47%
Both yoy CFO lines are negative, with RVPH at -0.02%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
72.96%
CapEx growth of 72.96% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.96%
We expand invests by 72.96% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
86.96%
Debt repayment growth of 86.96% while RVPH is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-90.54%
Negative yoy issuance while RVPH is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.